Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD352A in Relapsed or Refractory Multiple Myeloma
NCT02954796Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD352A in multiple myeloma (MM), sponsored by Seagen Inc. Primary endpoints: Type, incidence, severity, seriousness, and relatedness of adverse events and Incidence of dose-limiting toxicity. Started Dec 2016; status: terminated.
02
Drugs
SGN-CD352A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02954796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954796.